Jiangxi Jemincare Group Co. Ltd. has reported that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., recently received approvals for clinical trials of five of its drugs in the fields of cancer, kidney and infectious diseases.
Retinoic acid receptor-γ (RARγ) agonism is a key factor in CD8 T-cell-mediated immunity to infectious pathogens. The lack of studies on the effects of RARγ agonists on in vivo tumor growth of triple-negative (TNBC) or HER2+ breast cancers make it necessary to investigate whether RARγ could play a critical role in T-cell-mediated immunity in these breast cancers, using novel RARγ nuclear agonists.
HST-1021 is a novel mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) allosteric inhibitor identified using the Smart Allostery Platform, and is being developed for the potential treatment of tumors.
Elpiscience Biopharma Ltd. and Astellas Pharma Inc. have announced a research collaboration and license agreement for two novel bispecific macrophage engagers – ES-019 and another program.
Nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) plays a central role in cancer metabolism as well as in metabolism in healthy tissues. Remedy Plan Therapeutics Inc. has presented data on the first hyperbolic Nampt inhibitor – RPT-1G – for the potential treatment of acute myeloid leukemia (AML).
Biocytogen Pharmaceuticals Co. Ltd. and Ctm Biotech Co. Ltd. have reported progress in the development of a trispecific T-cell engager for an intracellular target.
From previous reports, there is evidence that cancer cells overexpress inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 (ITPRIPL1) to evade the immune system and promote tumor growth. Tissue samples from patients with non-small-cell lung cancer (NSCLC) were collected and used for studying the expression (intensity and extent) patterns of ITPRIPL1 and its diagnostic and prognostic value in this cancer type.
Legochem Biosciences Inc. signed a $1.7 billion licensing deal with Janssen Biotech Inc. for its Trop2-directed antibody-drug conjugate (ADC), closing the biggest technology transfer deal in Korean biotech history after Chong Kun Dang Pharmaceuticals Corp.
Senti Biosciences Inc. has received clearance of its IND application from the FDA for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33- and/or FLT3-expressing hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome, while sparing healthy bone marrow cells.
Fused pyrimidine compounds acting as menin (MEN1)/MLL interaction inhibitors have been described in a Biomea Fusion Inc. patent and reported to be useful for the treatment of cancer, osteoporosis, autoimmune and inflammatory diseases, among others.
RSS
